

television providers in Columbus. TCI and TeleCable are the two largest cable television providers in the Columbus area in terms of the number of subscribers and the number of homes passed.

the agreement containing consent order would, if finally issued by the Commission, settle charges alleged in the Commission's complaint that TCI's acquisition of TeleCable would substantially lessen competition in the distribution of multichannel video programming by cable television in the Columbus, Georgia, area, in violation of Section 7 of the Clayton Act. The nature of such competition to be preserved is actual competition to serve existing homes, hotels, and apartment complexes. The order will also preserve competition for providing cable service to new housing developments and other presently cabled portions of the Columbus area. The Commission's complaint further alleges that TCI's merger agreement with TeleCable violates Section 5 of the Federal Trade Commission Act.

The order accepted for public comment would require TCI to divest a cable television system in the Columbus, Georgia, area. If TCI fails to divest a system within one year, the order allows the Commission to appoint a trustee to sell a cable system. A hold separate agreement executed in conjunction with the consent agreement requires TCI, until completion of the divestiture (or as otherwise specified), to maintain TeleCable's Columbus cable system separate from TCI's other operations. For ten (10) years from the date the order becomes final, the order would also prohibit TCI, without obtaining prior Commission approval, from acquiring any cable television system in the Columbus, Georgia, area.

The purpose of this analysis is to invite public comment concerning the consent order. This analysis is not intended to constitute an official interpretation of the agreement and order or to modify their terms in any way.

By direction of the Commission.

Donald S. Clark,
Secretary.

[FR Doc. 95-4280 Filed 2-21-95; 8:45 am]

BILLING CODE 6750-01-M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Meeting

Pursuant to Pub. L. 92-463, notice is hereby given of the meeting of the Acrylonitrile Study Advisory Panel, National Cancer Institute, National Institutes of Health, on Friday March 24, 1995. The meeting will be held in Conference Room H, Executive Plaza North, 6130 Executive Boulevard, Rockville, Maryland 20892.

This meeting will be open to the public from 10 am to 5 pm for discussion and review of study progress. Attendance by the public will be limited to space available.

Ms. Carole A. Frank, Committee Management Officer, National Cancer Institute, Executive Plaza North, Room 630, National Institutes of Health, Bethesda, Maryland 20892 (301/496-5708) will provide summaries of the meeting and rosters of committee members, upon request.

Dr. Aaron Blair, Executive Secretary, Division of Cancer Etiology, National Cancer Institute, National Institutes of Health, Executive Plaza North, Room 418, 6130 Executive Boulevard, Rockville, Maryland 20892 (301/496-9093) will furnish substantive program information.

Individuals who plan to attend and need special assistance, such as sign language interpretation or other special accommodations, should contact Dr. Aaron Blair, (301) 496-9093, in advance of the meeting.

Dated: February 15, 1995.

Susan K. Feldman,

Committee Management Officer, National Institutes of Health.

[FR Doc. 95-4244 Filed 2-21-95; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Health

National Cancer Institute; Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the National Cancer Institute (NCI) advisory committee meetings.

These meetings will be open to the public as indicated below with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the contact person in advance of the meeting.

Ms. Carole Frank, NCI Committee Management Officer, National Institutes of Health, Executive Plaza North, Room 630E, 6130 Executive Boulevard MSC 7405, Bethesda, Maryland 20892-7405, (301) 496-5708, will provide summaries of the meetings and rosters of committee members upon request. Substantive program information may be obtained from the contacts listed below.

Committee Name: Developmental Therapeutics Contracts Review Committee.

Contact Person: Dr. C. Michael Kerwin, Scientific Review Administrator, DEA, NCI, NIH, Executive Plaza North, Room 601A, 6130 Executive Boulevard, Rockville, MD 20852-7405, Telephone: (301) 496-7421

Date of Meeting: March 3, 1995

Place of Meeting: Executive Plaza North, Conference Room J, 6130 Executive Boulevard, Rockville, MD 20852

Closed: 9 am to adjournment

Agenda: Review, discussion and evaluation of individual contract proposals.

Committee Name: Board of Scientific Counselors, Division of Cancer Biology, Diagnosis, and Centers

Contact person: Dr. Ihor J. Masnyk, Executive Secretary, NCI, NIH, Building 31A, Room 3A11, 9000 Rockville Pike, Bethesda, MD 20892-2440, Telephone: (301) 496-3251

Date of Meeting: March 6, 1995

Place of Meeting: Building 31C—Conference Room 10, National Institutes of Health, 9000 Rockville Pike, Rockville, MD 20892

Open: 8:30 am to adjournment

Agenda: Discussion and review of the division budget and review of concepts for grants and contracts.

These meetings will be closed, as indicated, in accordance with provisions set forth in secs. 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposals, disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the meeting due to the urgent need to meet timing limitations imposed by the review cycle.

(Catalog of Federal Domestic Assistance Program Numbers: 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control)